Literature DB >> 31259179

Nephro Update Europe 2018.

Nina Kesel1.   

Abstract

Keywords:  Diabetic nephropathy; Glomerulonephritis; Hepatitis C update; Hypertension update; Nephro Update Europe; Peritoneal dialysis

Year:  2019        PMID： 31259179      PMCID： PMC6587211          DOI： 10.1159/000499822

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN： 2296-9357


× No keyword cloud information.
  26 in total

1.  Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.

Authors:  Clara K Chow; Jay Thakkar; Alex Bennett; Graham Hillis; Michael Burke; Tim Usherwood; Kha Vo; Kris Rogers; Emily Atkins; Ruth Webster; Michael Chou; Hakim-Moulay Dehbi; Abdul Salam; Anushka Patel; Bruce Neal; David Peiris; Henry Krum; John Chalmers; Mark Nelson; Christopher M Reid; Mark Woodward; Sarah Hilmer; Simon Thom; Anthony Rodgers
Journal:  Lancet       Date:  2017-02-10       Impact factor: 79.321

2.  Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.

Authors:  Yao-Chun Hsu; Jaw-Town Lin; Hsiu J Ho; Yu-Hsi Kao; Yen-Tsung Huang; Nai-Wan Hsiao; Ming-Shiang Wu; Yi-Ya Liu; Chun-Ying Wu
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

3.  Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015.

Authors:  Mohammad H Forouzanfar; Patrick Liu; Gregory A Roth; Marie Ng; Stan Biryukov; Laurie Marczak; Lily Alexander; Kara Estep; Kalkidan Hassen Abate; Tomi F Akinyemiju; Raghib Ali; Nelson Alvis-Guzman; Peter Azzopardi; Amitava Banerjee; Till Bärnighausen; Arindam Basu; Tolesa Bekele; Derrick A Bennett; Sibhatu Biadgilign; Ferrán Catalá-López; Valery L Feigin; Joao C Fernandes; Florian Fischer; Alemseged Aregay Gebru; Philimon Gona; Rajeev Gupta; Graeme J Hankey; Jost B Jonas; Suzanne E Judd; Young-Ho Khang; Ardeshir Khosravi; Yun Jin Kim; Ruth W Kimokoti; Yoshihiro Kokubo; Dhaval Kolte; Alan Lopez; Paulo A Lotufo; Reza Malekzadeh; Yohannes Adama Melaku; George A Mensah; Awoke Misganaw; Ali H Mokdad; Andrew E Moran; Haseeb Nawaz; Bruce Neal; Frida Namnyak Ngalesoni; Takayoshi Ohkubo; Farshad Pourmalek; Anwar Rafay; Rajesh Kumar Rai; David Rojas-Rueda; Uchechukwu K Sampson; Itamar S Santos; Monika Sawhney; Aletta E Schutte; Sadaf G Sepanlou; Girma Temam Shifa; Ivy Shiue; Bemnet Amare Tedla; Amanda G Thrift; Marcello Tonelli; Thomas Truelsen; Nikolaos Tsilimparis; Kingsley Nnanna Ukwaja; Olalekan A Uthman; Tommi Vasankari; Narayanaswamy Venketasubramanian; Vasiliy Victorovich Vlassov; Theo Vos; Ronny Westerman; Lijing L Yan; Yuichiro Yano; Naohiro Yonemoto; Maysaa El Sayed Zaki; Christopher J L Murray
Journal:  JAMA       Date:  2017-01-10       Impact factor: 56.272

4.  Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis.

Authors:  David A Goodkin; Brian Bieber; Michel Jadoul; Paul Martin; Eiichiro Kanda; Ronald L Pisoni
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-01       Impact factor: 8.237

5.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

6.  Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Authors:  Christoph Wanner; John M Lachin; Silvio E Inzucchi; David Fitchett; Michaela Mattheus; Jyothis George; Hans J Woerle; Uli C Broedl; Maximilian von Eynatten; Bernard Zinman
Journal:  Circulation       Date:  2017-09-13       Impact factor: 29.690

7.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

8.  Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Annette Bruchfeld; David Roth; Paul Martin; David R Nelson; Stanislas Pol; Maria-Carlota Londoño; Howard Monsour; Marcelo Silva; Peggy Hwang; Jean-Marie Arduino; Michael Robertson; Bach-Yen Nguyen; Janice Wahl; Eliav Barr; Wayne Greaves
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-05-30

9.  Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.

Authors:  Haesuk Park; Chao Chen; Wei Wang; Linda Henry; Robert L Cook; David R Nelson
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

10.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Authors:  David Roth; David R Nelson; Annette Bruchfeld; AnnMarie Liapakis; Marcelo Silva; Howard Monsour; Paul Martin; Stanislas Pol; Maria-Carlota Londoño; Tarek Hassanein; Philippe J Zamor; Eli Zuckerman; Shuyan Wan; Beth Jackson; Bach-Yen Nguyen; Michael Robertson; Eliav Barr; Janice Wahl; Wayne Greaves
Journal:  Lancet       Date:  2015-10-05       Impact factor: 202.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.